Home > Newsletters > FDAnews Drug Daily Bulletin > FDA May Reinstate Oversight Policy as Warning Letter Quality Declines
FDAnews Drug Daily Bulletin
July 13, 2010 | Vol. 7 No. 135
FDA May Reinstate Oversight Policy as Warning Letter Quality Declines
Since FDA Commissioner Margaret Hamburg ended prior legal review of warning letters last summer, their quality has declined, industry says, prompting the agency to evaluate the policy change. “I have noticed what appears to be a diminution in the quality of warning letters — issues ranging from typographical errors to lack of legal support for assertions,” Jennifer Bragg, partner at Skadden, Arps, Slate, Meagher & Flom, said. In line with Hamburg’s commitment to ensure that the FDA’s work is factually and legally correct, the agency is evaluating the impact of the change, the FDA said.
Washington Drug Letter
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.